COPD Exacerbations and Increased Cardiovascular Risk

Published Online: Friday, January 17, 2014
Follow Pharmacy_Times:
In this podcast, Nitin Seam, MD, assistant professor of medicine at George Washington University, talks with Anant Patel, MBBS, MRC clinical research fellow at the Center for Respiratory Medicine, University College London, and Mark Dransfield, MD, associate professor of medicine at UAB School of Medicine and medical director of the UAB Lung Health Center, about a new study of the link between acute exacerbations of COPD and cardiovascular risk.

To listen to this podcast, click here.
Related Articles
Digoxin is associated with a 71% increased risk of death and a 63% higher risk of hospitalization among adults diagnosed with atrial fibrillation who have no evidence of heart failure.
Patients with chronic cardiovascular disease who receive automated reminders for their prescription blood pressure and cholesterol medications are more likely to refill those drugs.
A Genzyme and Isis Pharmaceuticals Inc. study suggests that mipomersen sodium injections reduce the odds of major adverse cardiovascular events in patients with familial hypercholesterolemia, compared with the 2 years prior to therapy.
A Merck study found patients who received a cholesterol-lowering combination of ezetimibe/simvastatin experienced fewer major cardiovascular events than those taking simvastatin alone.
Latest Issues
$auto_registration$